-

Hundreds take on Race the Light to support the Chilterns Neuro Centre
Hundreds of runners, walkers and families came together for a memorable evening at Race the Light, a spectacular trail running event organised by Runaway Racing in partnership with the Chilterns Neuro Centre, raising well over £3,000 to support local people affected by MS, Parkinson’s and strokes. Held in the beautiful surroundings of Wendover Woods, the…
-
EX DeFi Introduces AI-Powered Trading Technology Amid Growing Adoption of Artificial Intelligence in Financial Markets
New York City, NY, July 10, 2026 (GLOBE NEWSWIRE) — Global financial markets continued to experience heightened attention from investors as market participants monitored economic data, corporate earnings, and developments in artificial intelligence (AI) technologies across industries. Major stock markets showed mixed but stable performance, with investors continuing to assess economic conditions, monetary policy expectations,…
-

Kikkoman Hosts the 4th All-India Kikkoman Cooking Contest
Theme: ‘Surprising Ingredient Pairings’ – Students and Professionals Redefine the Potential of Kikkoman Naturally Brewed Soy Sauce NEW DELHI, July 1, 2026 /PRNewswire/ — On 26 February 2026, Kikkoman India hosted the 4th All-India Kikkoman Cooking Contest at IHM Pusa, Delhi. This year’s theme challenged participants to create an original dish featuring Kikkoman Soy Sauce through…
-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE…
-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.






